Skip to main content
Fig. 2 | BMC Anesthesiology

Fig. 2

From: Paravertebral dexmedetomidine as an adjuvant to ropivacaine protects against independent lung injury during one-lung ventilation: a preliminary randomized clinical trial

Fig. 2

Examination of lung injury by light microscopy following one-lung ventilation. Lung injury was indicated in edema, inflammatory cell infiltration and alveolar congestion (Fig. 2a. Histological analysis revealed severe lung injury in groups C and R. Lung injury was significantly decreased in the Div, RD0.5, RD1.0, and RD2.0 groups compared with the C and R groups. No differences were found among the Div, RD0.5, RD1.0 and RD2.0 groups. Figure 2b: aP<0.05 vs. the C group; bP<0.05 vs. the R group. Magnification ×200. C, normal saline; R, ropivacaine; Div, intravenous DEX; RD0.5, 0.5 μg/kg DEX as an adjuvant to ropivacaine TPVB; RD1.0, 1.0 μg/kg DEX as an adjuvant to ropivacaine TPVB; RD2.0, 2.0 μg/kg DEX as an adjuvant to ropivacaine TPVB

Back to article page